Publication Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Oncology Briefings Vol. 6, No. 8

Release Date: November 25, 2008
Expiration Date: November 25, 2009

Publication Overview

Authors

Medical writer:
Timothy Quill, PhD; Reviewed by:
Nancy Dawson, MD, FACP

Overview and Purpose

Prostate cancer is the most commonly diagnosed cancer in men. In 2008, it is estimated that > 186,000 men in the United States will be diagnosed with prostate cancer, and that > 28,000 will die from this disease. Androgen deprivation therapy is an important element in the control of advanced prostate cancer; however, eventually all patients develop hormone-refractory prostate cancer (HRPC). The current standard of care for these patients is a docetaxel-based regimen. However, the moderate survival increase obtained with these regimens is balanced against an increased toxicity profile. Recently, an increased understanding of the molecular characteristics of prostate tumor cells and their propensity to metastasize to bone has led to the development of novel targeted approaches. Several clinical trials are currently evaluating these targeted agents in patients with HRPC.

The purpose of this activity is to apprise physicians of the rationale for and clinical data on endothelinA receptor antagonists in the treatment of patients with HRPC.

Target Audience

This activity is intended for medical oncologists involved in the care of patients with prostate cancer. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.

Learning Objectives

Upon completion of this educational activity, you should be able to:

  • Review the importance of the endothelin axis in the development of bony disease in patients with prostate cancer
  • Evaluate the efficacy of cytotoxic and targeted agents in the treatment of HRPC
  • Assess the safety profile of cytotoxic and targeted agents in the treatment of HRPC

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. Study the educational activity.
  4. Complete the CME test.
  5. Answer the evaluation questions.
  6. After successful completion of the CME test and evaluation, you will receive your certificate of credit online.

CME credit will be granted for only 1 form of participation, either online or via the printed publication.

Read all of the conditions in the Activity Terms box below. You must accept the Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

Timothy Quill, PhD
No relevant relationships to disclose

Nancy Dawson, MD, FACP
Speaker’s Bureau – AstraZeneca

PER Editorial Staff
No relevant relationships to disclose

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the title page. Please refer to the full prescribing information for each drug discussed in this online newsletter for FDA-approved dosing, indications, and warnings.

Commercial Support
An educational grant for this activity was provided by AstraZeneca.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users If you need to upgrade your Web browser, follow one of the links listed below:

Macintosh Users Compatible Web browsers include Firefox (Outside Source) and Apple Safari (Outside Source)

Disclaimer

The views and opinions expressed in this activity are those of the authors and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the authors and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949–0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2008 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Oncology Briefings
Physicians’ Education Resource
 3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367–3400
Fax: (214) 367–3304
E–mail: editor@pergrouplp.com

Download a Print Version of this Publication*

*Print format is for reference only

Educational Grants

An educational grant for this activity was provided by:


  1. AstraZeneca